Liver Specimen Reference Sets

Organ Protocol ID Reference set title Cases Controls Total participants Participant groups Specimen type Number of specimens Volume range (mL) Specimens at NCI-F? Sequential samples? Follow-up data? Pathology Image files avail? Incident cancer?
Liver

316

Hepatocellular carcinoma Early Detection Strategy study (HEDS)

124 1599 1723 N/A Serum 49,117 0.100–5.0

N/A Plasma 50,236 0.011–5.0

⁠⁠

N/A DNA 1,398 0.01–0.05
Liver

111

DCP/Liver Ref set Rapid set

50 50 100 ⁠⁠ Serum 1,329 0.01–0.5 ⁠⁠ ⁠⁠ ⁠⁠ ⁠⁠ ⁠✓
⁠⁠

⁠⁠⁠⁠⁠

⁠⁠⁠

Plasma 731 ⁠0.2–0.5 ⁠⁠ ⁠⁠ ⁠⁠ ⁠⁠ ⁠⁠ ⁠⁠
⁠⁠⁠⁠Liver

111⁠⁠

⁠⁠DCP/Liver Ref set Validation set

⁠⁠427 432⁠⁠ 871 ⁠⁠⁠ Serum 10,815 0.01–1.0 ⁠⁠⁠✓ ⁠⁠⁠

Plasma 5,090 0.2–0.5
⁠Liver

468

TLC Virtual Repository Phase II

TBD TBD TBD N/A Plasma TBD TBD ‍‍‍⁠⁠⁠✓ ‍‍

‍‍‍

‍‍‍‍

‍‍TBD ‍TBD ‍TBD ‍N/A Serum TBD TBD ‍‍‍⁠⁠⁠✓ ‍‍‍ ‍‍‍‍

‍‍‍

‍‍‍

‍‍TBD ‍TBD ‍TBD ‍N/A‍ Plasma TBD TBD ⁠⁠⁠‍ ‍‍ ‍‍ ‍‍

‍TBD TBD TBD N/A Serum TBD TBD ‍‍‍
‍Liver

‍‍

‍TLC Virtual Repository Phase III

‍‍TBD ‍TBD ‍TBD ‍‍N/A Plasma TBD TBD ‍‍ ‍‍

‍‍

‍‍

‍TBD TBD TBD ‍N/A Serum TBD TBD

‍‍

‍‍

‍TBD TBD TBD ‍N/A Plasma TBD TBD

‍‍

‍‍

‍TBD TBD TBD ‍N/A Serum TBD TBD
Liver

491

TLC LR3/LR4 Prospective Prevalidation

TBD TBD TBD N/A Serum TBD TBD N/A TBD

Plasma TBD TBD N/A TBD
Liver

491

TLC LR3/LR4 Prospective Validation

TBD TBD TBD N/A Serum TBD TBD N/A TBD

Plasma TBD TBD N/A TBD